Last 48 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 0.24 | 41.56 | 0.64 | — | 0.23 | — | — | 1.68 | 0.74 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | -68.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.56 | 3.82 | — | 1.84 | 6.95 | 11.51 | 3.97 | 2.86 | — | 0.22 | 22.32 | 2.29 | 20.11 | 13.20 | 37.21 | 305.39 | 273.95 | 484.55 | 206.98 | 114.91 | 494.21 |
| — | -66.8% | — | -35.8% | — | +5210.9% | -82.2% | +24.6% | — | -98.4% | -40.0% | -99.2% | -92.7% | -97.3% | -82.0% | +165.8% | -44.6% | +1174.9% | -67.2% | -77.8% | +52.0% | |
| P/B Ratio | 1.84 | 1.88 | — | — | 7.93 | 2.83 | — | — | — | — | — | — | — | — | — | — | — | 659.08 | 199.42 | 157.06 | 142.74 |
| — | -33.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +859.1% | -9.2% | -23.0% | -25.5% | |
| P/FCF | — | — | — | — | — | — | 0.42 | 2.89 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.4% | — | 100.1% | -9.8% | 136.3% | 87.5% | 77.3% | 78.9% | 83.2% | 88.6% | -3156.5% | -128.0% | 80.1% | 89.4% | 87.1% | 90.3% | 85.7% | 72.6% | 77.2% | -53.3% | 65.5% |
| — | — | +29.5% | -112.5% | +63.7% | -1.2% | +102.4% | +161.6% | +3.9% | -1.0% | -3723.2% | -241.7% | -6.5% | +23.1% | +12.9% | +269.5% | +30.8% | +47.4% | +118.6% | +48.3% | -31.8% | |
| Operating Margin | -712.7% | -730.1% | 1192.3% | -369.7% | -1102.0% | -499.1% | -864.9% | -540.1% | 74.4% | -36.2% | -4650.1% | -193.9% | -199.7% | -158.2% | -198.7% | -210.4% | -192.5% | -595.2% | -262.4% | -103.6% | -817.5% |
| — | -46.3% | +237.8% | +31.6% | -1581.9% | -1278.2% | +81.4% | -178.6% | +137.2% | +77.1% | -2240.6% | +7.8% | -3.7% | +73.4% | +24.3% | -103.2% | +76.5% | -1921.3% | +52.2% | +43.5% | -816.2% | |
| Net Margin | 2848.6% | 8.9% | -812.3% | -406.6% | 2971.3% | 13798.6% | -564.0% | 169.4% | -14.6% | -36.9% | -1557.5% | -129.8% | -207.2% | -158.5% | -197.8% | -212.1% | -192.6% | -582.5% | -243.7% | -103.9% | -810.5% |
| — | -99.9% | -44.0% | -340.1% | +20466.3% | +37522.8% | +63.8% | +230.4% | +93.0% | +76.7% | -687.3% | +38.8% | -7.6% | +72.8% | +18.8% | -104.1% | +76.2% | -1924.3% | +55.7% | +44.4% | -798.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4099.5% | 5.1% | — | — | 345.6% | 849.1% | — | — | — | — | — | — | — | — | — | — | -295.5% | -107.8% | -48.1% | -31.0% | -46.7% |
| — | -99.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -532.7% | -776.5% | -20.4% | -79.9% | -263.4% | |
| ROA | 109.8% | 0.2% | 11.4% | -13.3% | 29.6% | 94.2% | -4.4% | 2.4% | 7.5% | -6.1% | -4.7% | -9.0% | -12.7% | -13.0% | -16.6% | -13.4% | -10.9% | -14.1% | -10.1% | -8.3% | -16.5% |
| — | -99.8% | +356.6% | -642.7% | +293.8% | +1638.1% | +6.1% | +127.1% | +159.0% | +53.0% | +71.7% | +32.6% | -17.2% | +7.8% | -64.2% | -60.6% | +34.2% | -335.7% | +39.6% | +6.4% | -130.7% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -426.2% | -84.4% | -38.3% | -61.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1238.8% | +89.0% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 1.20 | — | — | — | — | — | — | — | — | — | — | — | 2.00 | 0.76 | 0.54 | 0.44 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +574.8% | +102.7% | +458.8% | +383.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.39 | 1.16 | 2.69 | 3.61 | 3.39 | 3.71 | 1.04 | 2.02 | 1.47 | 1.28 | 1.41 | 1.41 | 1.52 | 1.74 | 2.12 | 1.69 | 1.80 | 1.88 | 2.17 | 2.05 | 2.10 |
| — | -68.6% | +158.0% | +78.1% | +129.8% | +189.0% | -26.1% | +43.1% | -3.2% | -26.2% | -33.5% | -16.3% | -15.4% | -7.6% | -2.2% | -17.7% | -14.3% | -31.3% | -10.7% | -44.8% | -54.6% | |
| Quick Ratio | 3.26 | 1.09 | 2.59 | 3.48 | 3.26 | 3.60 | 1.02 | 1.98 | 1.45 | 1.16 | 1.24 | 1.27 | 1.33 | 1.54 | 1.91 | 1.52 | 1.65 | 1.72 | 2.00 | 1.88 | 1.96 |
| — | -69.8% | +155.1% | +75.9% | +124.8% | +211.1% | -17.9% | +55.4% | +8.9% | -25.0% | -35.1% | -16.3% | -19.4% | -10.4% | -4.4% | -19.2% | -15.8% | -33.7% | -13.9% | -47.6% | -56.6% | |
| Interest Coverage | -6.66 | -7.88 | -20.90 | -5.23 | -8.70 | -5.31 | -5.86 | -6.43 | — | -2.60 | -24.36 | -22.44 | -10.69 | -12.64 | -28.69 | -32.08 | -59.12 | -1114.96 | -554.78 | -150.34 | -1229.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KYNB stock.
Kyntra Bio, Inc.'s current P/E is 0.2x. The average P/E over the last 3 quarters is 14.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Kyntra Bio, Inc.'s current operating margin is -712.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Kyntra Bio, Inc.'s business trajectory between earnings reports.